Skip to main content
Publications
Kovesdy CP, Layton JB , Thapa BB, Curhan GC, Rangel LM, Farjat AE, Liu F, Johannes CB , Vizcaya D, Oberprieler NG. Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in people with CKD and type 2 diabetes initiating finerenone: a comedication subgroup analysis from the FOUNTAIN platform . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 24, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):559.
Kovesdy CP, Layton JB , Thapa BB, Curhan GC, Rangel LM, Farjat AE, Liu F, Johannes CB , Vizcaya D, Oberprieler NG. Reduction in Urinary Albumin-to-Creatinine Ratio (UACR) in people with CKD and type 2 diabetes initiating finerenone: a CKD stage subgroup analysis from the FOUNTAIN platform . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 25, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):559.
Ayoub I, Bensink ME, Zhou X , Wang J , Gong W, Preciado P, Komers R, Inrig JK, Rheault MN, Tachtman H. Patient-reported outcomes in adults with FSGS: sparsentan vs. irbesartan . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):281.
Wadhwani S, Bensink M, Peipert JD, Ayoub I, Preciado P, Garbinsky D , Bennett L , Gong W, Inrig J, Komers R. Patient-reported outcomes in the PROTECT clinical trial comparing sparsentan with irbesartan for IgA nephropathy . Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):723.
Ilomaki J, Bell JS, Chan EW, Tolppanen A-M, Luo H, Wei L, Lai EC, Shin J-U, De Paoli G, Pajouheshnia R , Ho FK, Reynolds L, Lau KK, Crystal S, Lau WCY, Man KKC, Brauer R, Chan AYL, Shen C-Y, Kim JH, Lum TYS, Hartikainen S, Koponen M, Rooke E, Bazelier M, Klungel O, Setoguchi S, Pell JP, Cook S, Wong ICK. Application of healthcare 'big data' in CNS drug research: the example of the neurological and mental health global epidemiology network (NeuroGEN) . CNS Drugs. 2020 Sep;34(9):897-913. doi: 10.1007/s40263-020-00742-4
Pladevall-Vila M , Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J , Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Brandt L, Cortes J, Aguado J , Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S . Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources . CNS Drugs. 2019 Apr;33(4):383-95. doi: 10.1007/s40263-019-00611-9
Gilbertson DT, Rothman KJ , Chertow GM, Bradbury BD, Brookhart MA, Liu L, Winkelmayer WC, Sturmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB. Excess deaths attributable to influenza-like illness in the ESRD population . J Am Soc Nephrol. 2019 Feb;30(2):346-53. doi: 10.1681/ASN.2018060581
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ , Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform . J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232